Market Intelligence, Clinical Progress, and High-Purity Reagents for Cancer Immunotherapy Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for ROR1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | ROR1 ECD-Fc Fusion Protein / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed. |
View ROR1 Products |
| Gene Delivery | ROR1 Lentivirus (Promise-ORF) Premade Particles Full-length ORF for stable cell lines. Endotoxin Controlled. |
View ROR1 Products |
| Benchmark Ab | Anti-ROR1 (Sequence of Zilovertamab) Recombinant positive control. Sequence Verified. |
View ROR1 Products |
| Validator | ROR1 siRNA Set For knockdown verification. Validated sequences. |
View ROR1 Products |
| Related Target (Off-Target) | ROR2 Paralog receptor, critical for selectivity and counter-screening. |
View ROR2 Products |
| Related Target (Pathway) | WNT5A Primary ligand driving ROR1 signaling and tumor progression. |
View WNT5A Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species cyno/mouse evaluation | Human/Mouse/Cyno ortholog proteins available with >95% purity, Sequence Verified |
| ROR1 vs ROR2 selectivity / Subfamily counter screening | Homolog panel proteins strictly verified by mass spec for epitope specificity |
| Internalization efficiency | High-purity ECD-Fc with intact extracellular domain for accurate binding kinetics |
| Lack of Controls | Clinical Benchmark Antibodies (Zilovertamab biosimilar) included |
| False Positives | Validated siRNA included for specificity checks |
Live ROR1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for ROR1 therapeutics is intensifying, with major players shifting focus from traditional mAbs to Antibody-Drug Conjugates (ADCs) and Cell Therapies. As first-generation therapies (Zilovertamab vedotin) advance to Phase 2/3, the next wave of R&D is targeting combination strategies with checkpoint inhibitors and novel CAR-macrophage modalities for solid tumor penetration. Optimizing internalization efficiency and bystander effect are key for next-generation ADCs, while bispecifics (CD3/ROR1) and CAR-T approaches are expanding into solid tumors.
Competitive Modality & Indication Snapshot
Connect market trends to assay needs.
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ADC | Merck (VelosBio), BeiGene, NBE-Therapeutics | Hematological & Solid Tumors (CLL, TNBC) | Internalization Assay (Need high-purity ECD-Fc) |
| CAR-T | Precision BioSciences, CARisma, Lyell Immunopharma, BMS | Hematologic Malignancies (MCL, TNBC) | Cell Surface Expression Validation (Need Lentivirus) |
| Bispecific | Oncternal Therapeutics, Various | CLL, Solid Tumors | Cross-reactivity Assay (Need ROR1/ROR2 panel) |
| mAb | Oncternal (Cirmtuzumab) | CLL | Binding Affinity (Need high-purity antigen) |